Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival

Michelle A. Elliott, Mark R Litzow, Louis L. Letendre, Robert C. Wolf, Curtis A. Hanson, Ayalew Tefferi, Martin S. Tallman

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

In childhood acute lymphoblastic leukemia (ALL), a rapid decline of circulating leukemic blasts in response to induction chemotherapy or prednisone is one of the most important prognostic factors, not only for achieving remission but also for relapse-free survival (RFS). However, in acute myeloid leukemia (AML) parameters of chemosensitivity have been restricted mainly to the rapidity of achievement of complete remission (CR) or the assessment of residual leukemic bone marrow blasts during aplasia. We hypothesized that the time to circulating peripheral blood blast clearance, as a potential surrogate for in vivo chemosensitivity, would have prognostic relevance in AML also. In a retrospective analysis of a cohort of 86 adult patients with AML receiving uniform induction and consolidation chemotherapy, we demonstrate that the time to clearance of circulating blasts during induction chemotherapy is an independent prognostic marker of RFS, superseding other known or established risk factors, including karyotype and number of inductions to achieve CR.

Original languageEnglish (US)
Pages (from-to)4172-4174
Number of pages3
JournalBlood
Volume110
Issue number13
DOIs
StatePublished - Dec 15 2007

Fingerprint

Induction Chemotherapy
Chemotherapy
Acute Myeloid Leukemia
Blood
Recurrence
Survival
Consolidation Chemotherapy
Prednisone
Karyotype
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Consolidation
Bone
Cohort Studies
Bone Marrow

ASJC Scopus subject areas

  • Hematology

Cite this

Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival. / Elliott, Michelle A.; Litzow, Mark R; Letendre, Louis L.; Wolf, Robert C.; Hanson, Curtis A.; Tefferi, Ayalew; Tallman, Martin S.

In: Blood, Vol. 110, No. 13, 15.12.2007, p. 4172-4174.

Research output: Contribution to journalArticle

Elliott, Michelle A. ; Litzow, Mark R ; Letendre, Louis L. ; Wolf, Robert C. ; Hanson, Curtis A. ; Tefferi, Ayalew ; Tallman, Martin S. / Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival. In: Blood. 2007 ; Vol. 110, No. 13. pp. 4172-4174.
@article{1258f200cb7f4adaabc2ffbe701cde7b,
title = "Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival",
abstract = "In childhood acute lymphoblastic leukemia (ALL), a rapid decline of circulating leukemic blasts in response to induction chemotherapy or prednisone is one of the most important prognostic factors, not only for achieving remission but also for relapse-free survival (RFS). However, in acute myeloid leukemia (AML) parameters of chemosensitivity have been restricted mainly to the rapidity of achievement of complete remission (CR) or the assessment of residual leukemic bone marrow blasts during aplasia. We hypothesized that the time to circulating peripheral blood blast clearance, as a potential surrogate for in vivo chemosensitivity, would have prognostic relevance in AML also. In a retrospective analysis of a cohort of 86 adult patients with AML receiving uniform induction and consolidation chemotherapy, we demonstrate that the time to clearance of circulating blasts during induction chemotherapy is an independent prognostic marker of RFS, superseding other known or established risk factors, including karyotype and number of inductions to achieve CR.",
author = "Elliott, {Michelle A.} and Litzow, {Mark R} and Letendre, {Louis L.} and Wolf, {Robert C.} and Hanson, {Curtis A.} and Ayalew Tefferi and Tallman, {Martin S.}",
year = "2007",
month = "12",
day = "15",
doi = "10.1182/blood-2007-07-104091",
language = "English (US)",
volume = "110",
pages = "4172--4174",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "13",

}

TY - JOUR

T1 - Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival

AU - Elliott, Michelle A.

AU - Litzow, Mark R

AU - Letendre, Louis L.

AU - Wolf, Robert C.

AU - Hanson, Curtis A.

AU - Tefferi, Ayalew

AU - Tallman, Martin S.

PY - 2007/12/15

Y1 - 2007/12/15

N2 - In childhood acute lymphoblastic leukemia (ALL), a rapid decline of circulating leukemic blasts in response to induction chemotherapy or prednisone is one of the most important prognostic factors, not only for achieving remission but also for relapse-free survival (RFS). However, in acute myeloid leukemia (AML) parameters of chemosensitivity have been restricted mainly to the rapidity of achievement of complete remission (CR) or the assessment of residual leukemic bone marrow blasts during aplasia. We hypothesized that the time to circulating peripheral blood blast clearance, as a potential surrogate for in vivo chemosensitivity, would have prognostic relevance in AML also. In a retrospective analysis of a cohort of 86 adult patients with AML receiving uniform induction and consolidation chemotherapy, we demonstrate that the time to clearance of circulating blasts during induction chemotherapy is an independent prognostic marker of RFS, superseding other known or established risk factors, including karyotype and number of inductions to achieve CR.

AB - In childhood acute lymphoblastic leukemia (ALL), a rapid decline of circulating leukemic blasts in response to induction chemotherapy or prednisone is one of the most important prognostic factors, not only for achieving remission but also for relapse-free survival (RFS). However, in acute myeloid leukemia (AML) parameters of chemosensitivity have been restricted mainly to the rapidity of achievement of complete remission (CR) or the assessment of residual leukemic bone marrow blasts during aplasia. We hypothesized that the time to circulating peripheral blood blast clearance, as a potential surrogate for in vivo chemosensitivity, would have prognostic relevance in AML also. In a retrospective analysis of a cohort of 86 adult patients with AML receiving uniform induction and consolidation chemotherapy, we demonstrate that the time to clearance of circulating blasts during induction chemotherapy is an independent prognostic marker of RFS, superseding other known or established risk factors, including karyotype and number of inductions to achieve CR.

UR - http://www.scopus.com/inward/record.url?scp=38949183169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38949183169&partnerID=8YFLogxK

U2 - 10.1182/blood-2007-07-104091

DO - 10.1182/blood-2007-07-104091

M3 - Article

VL - 110

SP - 4172

EP - 4174

JO - Blood

JF - Blood

SN - 0006-4971

IS - 13

ER -